Levofloxacin and Sparfloxacin: New Quinolone Antibiotics (Q37881273)

24 August 2017

1 reference

title

Levofloxacin and sparfloxacin: new quinolone antibiotics (English)

1 reference

24 August 2017

Levofloxacin and Sparfloxacin: New Quinolone Antibiotics (English)

1 reference

16 December 2024

0 references

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:9533064

16 December 2024

author name string

S. J. Martin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:9533064

16 December 2024

J. M. Meyer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:9533064

16 December 2024

S. K. Chuck

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:9533064

16 December 2024

R. Jung

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:9533064

16 December 2024

C. R. Messick

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:9533064

16 December 2024

S. L. Pendland

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:9533064

16 December 2024

language of work or name

English

0 references

publication date

1 March 1998

1 reference

24 August 2017

March 1998

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9533064

full work available at URL

16 December 2024

https://journals.sagepub.com/doi/pdf/10.1345/aph.17178

1 reference

Annals of Pharmacotherapy

16 December 2024

published in

1 reference

24 August 2017

volume

32

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

320-336

1 reference

DNA Gyrase and the Supercoiling of DNA

24 August 2017

cites work

1 reference

Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates

21 January 2018

1 reference

Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfioxacin, tosufloxacin, CI-960 and CI-990

21 January 2018

1 reference

In vitro activity of sparfloxacin

21 January 2018

1 reference

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

21 January 2018

1 reference

Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones

21 January 2018

1 reference

In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds

21 January 2018

1 reference

Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents.

21 January 2018

1 reference

Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer

21 January 2018

1 reference

Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin

21 January 2018

1 reference

Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro

21 January 2018

1 reference

A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy

21 January 2018

1 reference

In vitro activity of sparfloxacin compared with those of five other quinolones

21 January 2018

1 reference

Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis

21 January 2018

1 reference

In vitro activity of S-ofloxacin

21 January 2018

1 reference

Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria

21 January 2018

1 reference

In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistantStaphylococcus aureus andStaphylococcus epidermidis

21 January 2018

1 reference

In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.

21 January 2018

1 reference

Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci

21 January 2018

1 reference

Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci

21 January 2018

1 reference

Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin

21 January 2018

1 reference

In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria.

21 January 2018

1 reference

In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci.

21 January 2018

1 reference

Comparative activities of eight quinolones against members of the Bacteroides fragilis group

21 January 2018

1 reference

Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria

21 January 2018

1 reference

Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria

21 January 2018

1 reference

Sparfloxacin worldwide in vitro literature: isolate data available through 1994.

21 January 2018

1 reference

In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent

21 January 2018

1 reference

In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

21 January 2018

1 reference

In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis

21 January 2018

1 reference

Comparative in-vitro activity of sparfloxacin against genital pathogens

21 January 2018

1 reference

In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens

21 January 2018

1 reference

In-vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics

21 January 2018

1 reference

In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia.

21 January 2018

1 reference

In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae

21 January 2018

1 reference

In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae

21 January 2018

1 reference

In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae

21 January 2018

1 reference

Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin

21 January 2018

1 reference

In-vitro activity of quinolones and macrolides against mycobacteria.

21 January 2018

1 reference

In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis

21 January 2018

1 reference

Anti-Mycobacterium avium activity of quinolones: in vitro activities

21 January 2018

1 reference

CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum

21 January 2018

1 reference

In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin

21 January 2018

1 reference

Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis

21 January 2018

1 reference

In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin

21 January 2018

1 reference

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

21 January 2018

1 reference

Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review

21 January 2018

1 reference

Clinical pharmacokinetics of sparfloxacin

21 January 2018

1 reference

Enantioselective disposition of ofloxacin in humans

21 January 2018

1 reference

Fluoroquinolone antimicrobial agents

21 January 2018

1 reference

Dose ranging study and constant infusion evaluation of ciprofloxacin

21 January 2018

1 reference

Pharmacokinetics and inflammatory fluid penetration of sparfloxacin

21 January 2018

1 reference

A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses

21 January 2018

1 reference

The penetration of sparfloxacin into human plasma and skin tissues

21 January 2018

1 reference

Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells

21 January 2018

1 reference

Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid

21 January 2018

1 reference

Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells

21 January 2018

1 reference

Pharmacokinetics of sparfloxacin in patients with renal impairment

21 January 2018

1 reference

Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases

21 January 2018

1 reference

Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin

21 January 2018

1 reference

Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group

21 January 2018

1 reference

Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study

21 January 2018

1 reference

Comparative efficacy and safety of single oral doses of sparfloxacin versus ciprofloxacin in the treatment of acute gonococcal urethritis in men.

21 January 2018

1 reference

A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of non-gonococcal urethritis in men.

21 January 2018

1 reference

Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light

21 January 2018

1 reference

Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation

21 January 2018

1 reference

Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group.

21 January 2018

1 reference

Safety profile of sparfloxacin in the treatment of respiratory tract infections

21 January 2018

1 reference

Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review

21 January 2018

1 reference

Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers

21 January 2018

1 reference

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group

21 January 2018

1 reference

Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide

21 January 2018

1 reference

Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients

21 January 2018

1 reference

In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens

21 January 2018

1 reference

Central nervous system toxicity of quinolones: human and animal findings

21 January 2018

1 reference

In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens

21 January 2018

1 reference

Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin

21 January 2018

1 reference

In vitro Activity of Sparfloxacin and Six Reference Antibiotics against Gram-Positive Bacteria

21 January 2018

1 reference

In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993

21 January 2018

1 reference

The in-vitro susceptibilities of 326 Streptococcus pneumoniae isolates to nine antimicrobial agents including penicillin and newer quinolones

21 January 2018

1 reference

Comparison of the in vitro activity of levofloxacin and other antimicrobial agents against vancomycin-susceptible and vancomycin-resistant Enterococcus species

21 January 2018

1 reference

In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci

21 January 2018

1 reference

Activity of sparfloxacin (AT-4140), PD127391 and PD131628 against Legionella spp

21 January 2018

1 reference

Comparative pharmacokinetics of new quinolones.

21 January 2018

1 reference

Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections

21 January 2018

1 reference

Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils

21 January 2018

1 reference

Effect of antimicrobial agents on the uptake of ofloxacin and its optically active isomer (—)-ofloxacin by human polymorphonuclear leucocytes

21 January 2018

1 reference

Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group

21 January 2018

1 reference

Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. Sinusitis Study Group

21 January 2018

1 reference

Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection

21 January 2018

1 reference

Sparfloxacin in the treatment of males with urethritis

21 January 2018

1 reference

Effect of ferrous sulfate on the absorption of sparfloxacin in healthy volunteers and rats

21 January 2018

1 reference

Effect of fenbufen on the penetration of quinolone antibiotics into cerebrospinal fluid. Comparative study with 5 quinolones

21 January 2018

1 reference

Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association

21 January 2018

1 reference

Mechanism of differential activities of ofloxacin enantiomers

21 January 2018

1

1 reference

Classification and structure-activity relationships of fluoroquinolones

16 December 2024

2

1 reference

Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem

16 December 2024

17

1 reference

In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin.

16 December 2024

38

1 reference

Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

16 December 2024

41

1 reference

In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis

16 December 2024

59

1 reference

Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine

16 December 2024

62

1 reference

Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994.

16 December 2024

66

1 reference

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

16 December 2024

106

1 reference

Clinical Infectious Diseases

16 December 2024

111

23

914

DeAbate CA

1996

1 reference

The Journal of Rheumatology

16 December 2024

134

23

516

Zabraniecki L

1996

1 reference

Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine

16 December 2024

144

1 reference

16 December 2024

Identifiers

DOI

10.1345/APH.17178

1 reference

24 August 2017

1 reference